Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
News Dec 04, 2007
Rosetta Genomics has announced that in preparation for the launch of its first microRNA-based diagnostic products in 2008, it is strengthening its management team.
Ronen Tamir has been appointed to the newly created position of Executive Vice President, Marketing and Communication, and will lead the commercialization of the company's first-ever microRNA-based diagnostic products.
"I am very pleased to announce the addition of such an accomplished pharmaceutical executive to our management team," said Amir Avniel, President and CEO of Rosetta Genomics. "Ronen brings with him a successful marketing, investor relations and communications background. His energy and leadership skills will be instrumental to the successful commercialization of our microRNA based products."
Prior to joining Rosetta Genomics, Ronen Tamir was Vice President, Investor Relations for North America at Novartis AG. While Ronen was at Novartis, Novartis significantly increased its North American shareholder base and Ronen's team won numerous awards, including the "Best European IR Team in North America for 2005" by IR magazine, the "Silver Anvil" award by the Public Relations Society of America, and the "Big Apple - Best of the Best" award by the Institution of Public Relations, both for Investor Relations campaign for 2006.
Prior to joining Novartis in 2004, Ronen held several key positions at Serono, including Director of Business Intelligence for North America and Global Product Manager, Neurology, in Geneva, Switzerland, where he oversaw the global launch of Rebif®, the leading therapy for Multiple Sclerosis. In addition, Ronen was the Regional Product Manager for Neurology and Metabolism for Serono's Intercontinental Business Operations.
Ronen holds a degree in Biology from Bar-Ilan University in Israel and an MBA from Warwick Business School in the UK.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.